ETX-636

ETX-636 is a novel, orally bioavailable small molecule developed by Ensem Therapeutics. It acts as an allosteric, pan-mutant-selective inhibitor and degrader of phosphoinositide 3-kinase alpha (PI3Kα). This dual mechanism—selective inhibition and targeted degradation—enables deep and durable suppression of mutant PI3Kα signaling in cancer cells while sparing wildtype PI3Kα, thereby reducing the risk of hyperglycemia and other toxicities associated with non-selective PI3Kα inhibitors. Preclinical studies have demonstrated potent activity against all mutant forms of PI3Kα in vitro and in vivo, including efficacy as a single agent and synergistic effects when combined with fulvestrant in ER-positive, HER2-negative breast cancer models. ETX-636 is being developed primarily for oncology indications involving tumors harboring PI3Kα mutations[1][2][6].